 - In Part 1 and, Part 2, subjects must have AML, MM, or NHL. Subjects with AML, are eligible if they have relapsed andor refractory disease, OR are65 years of age and not candidates for or have refused standard chemotherapy. Subjects with multiple myeloma are eligible if they have progressed despite therapy with an alkylating agent, proteasome inhibitor, and immunomodulatory agent, either as individual regimens or in combination. Subjects with NHL are eligible if they have received at least two prior lines of systemic therapy, including at least one line of immunochemotherapy with an anti-CD20 antibody if their tumor expresses CD20. 